



## VYXEOS™

*In vitro* research has shown that a 5:1 ratio of cytarabine:daunorubicin delivers optimal anti-cancer activity.<sup>1</sup>

VYXEOS™ is a liposomal formulation containing a synergistic 5:1 molar ratio containing cytarabine and daunorubicin.<sup>2</sup>

A completed Phase 3 study demonstrated improved survival for VYXEOS™ compared to "7+3" in newly diagnosed patients with high-risk AML.